Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Redhill Biopharma Ltd (NASDAQ:RDHL)

Tuesday’s Trading Day
12.09 -0.27 / -2.18%
As of Nov 24
Day’s Change
Wednesday’s Pre-Market   Switch to standard view »
12.74 +0.65 / +5.38%
Volume: 2.3K
Health Technology

Company Description

RedHill Biopharma Ltd. is a biopharmaceutical company, which engages in the development and acquisition of late clinical-stage, proprietary, and orally-administered drugs for the treatment of inflammatory and gastrointestinal diseases. Its product pipeline includes RHB-105, RHB-104, RHB-106, Bekinda, ABC294640, Mesupron, RP101, and Rizaport. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

Contact Information

RedHill Biopharma Ltd.
21 Ha'arba'a Street
Tel Aviv Tel Aviv 64739
P:(723) 541-3131
Investor Relations:



Other institutional21.94%
Mutual fund holders1.28%
Individual stakeholders--

Top Executives

Dror Ben-AsherChairman & Chief Executive Officer
Ori ShiloDirector, Deputy CEO-Finance & Operations
Clara FehrmannDirector-Clinical Operations
Ira N. KalfusMedical Director
Reza FathiSenior Vice President-Research & Development